MedTrace Logo

Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B

NCT04182321 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-12-07

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of metformin as add-on to entecavir therapy in patients with chronic hepatitis B.

Conditions

Interventions

DRUG

Metformin & Entecavir

Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)

DRUG

Placebo & Entecavir

Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)

Sponsors & Collaborators

  • Jinan Military General Hospital

    collaborator OTHER

  • Fu-Sheng Wang

    lead OTHER

Principal Investigators

  • Fu-Sheng Wang · The Fifth Medical Center of Chinese PLA General Hospital (Beijing 302 Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-13
Primary Completion
2021-07-02
Completion
2021-09-13

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04182321 on ClinicalTrials.gov